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PARDIOVASCULAR GENOMIC MEDICINE
olecular and Cellular Imaging of Atherosclerosis
merging Applications
arouc A. Jaffer, MD, PHD,*†§ Peter Libby, MD, FACC,*‡§ Ralph Weissleder, MD, PHD*§
harlestown and Boston, Massachusetts
Molecular imaging studies have shed light on important biological aspects of atherosclerosis,
and are now entering the clinical arena for the detection of clinical atheroma. This review first
discusses fundamental principles regarding the rationale for and development of molecular
imaging technologies for investigating atherosclerosis. Next, we highlight clinically promising
imaging strategies that illuminate key biological aspects of atherosclerosis, including macro-
phage activity, protease activity, lipoprotein presence, apoptosis, and angiogenesis. We envision
that several molecular imaging approaches will become important adjuncts to the clinical
management of high-risk atherosclerosis. (J Am Coll Cardiol 2006;47:1328–38) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.029the American College of Cardiology Foundation
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solecular imaging is a rapidly evolving discipline that aims
o develop imaging agents and technologies to visualize
pecific molecular processes in vivo. With a considerable
rack record in the biological sciences and drug discovery
1–7), molecular imaging is now poised to make significant
ontributions to clinical imaging of atherosclerosis (8).
dvances in atherosclerosis biology (9–13), imaging agent
hemistry (nanotechnology, chemical biology screens), and
maging platforms (magnetic resonance imaging [MRI],
ntegrated nuclear-computed tomography imaging, optical
maging, and ultrasound imaging) continue to drive this
rogress from bench to bedside.
In this review, we present recent developments in molec-
lar and cellular imaging of atherosclerotic vascular disease.
he discussion comprises several sections. First, we provide
rationale for employing molecular imaging strategies in
he detection of clinical atheromata. Next, we provide a
iological framework for designing atherosclerosis-targeted
maging agents, and briefly summarize various technical
spects of molecular agent development. We then consider
few clinically promising applications of molecular imaging
or high-risk atherosclerosis.
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F ATHEROSCLEROSIS BEYOND ANATOMY
ia its sequelae of myocardial infarction and stroke, athero-
clerotic vascular disease threatens to become a leading
ause of death worldwide by the year 2020 (14). As
igh-risk or vulnerable plaques are often unrecognized
efore causing clinical events, there is an unmet need to
dentify these plaques before the onset of symptoms (15–
7). This recognition has motivated the development of a
umber of noninvasive and invasive diagnostic imaging
trategies to permit identification of high-risk individuals,
ased on the presence of high-risk anatomical or structural
eatures of plaques (18–20). Recognizing that the multiplic-
ty of so-called vulnerable plaques necessitates both local
nd global treatment strategies (21), the present discussion
mphasizes the role of atherosclerosis imaging in the iden-
ification and management of the high-risk patient rather
han solely individual lesions.
In contrast with existing imaging approaches that primar-
ly aim to assess structural components of atherosclerosis
e.g., fibrous cap thickness, the size of the lipid core),
olecular and cellular imaging aims to image biological
roperties of atherosclerotic plaques in vivo (6–8,22–27).
he fundamental motivation for this approach stems from
he recognition that molecular and cellular processes govern
ll phases of atherogenesis, including plaque progression
nd plaque rupture (10). The ability to visualize specific
iological aspects of atherosclerotic lesions could have utility
n a number of different clinical scenarios, such as: 1)
roviding new diagnostic imaging capabilities for detecting
igh-risk plaques before symptom onset; 2) offering the
otential of personalized medicine (28) to guide the initia-
ion and titration of molecularly based atherosclerotic ther-
pies (e.g., a measure of plaque macrophage activity could
irect novel antimacrophage molecular therapies); and 3)
upplying imaging end points for clinical trials to assess the
fficacy of novel atherosclerotic therapeutics, as a prelude to
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erum biomarker discovery for atherosclerosis risk assess-
ent (29), specific molecular markers provide a foundation
or the construction of atherosclerosis-targeted imaging
gents. Table 1 summarizes promising targets, shown in the
ontext of the biology of atherosclerosis in Figure 1.
HE BIOLOGY OF ATHEROSCLEROSIS PROVIDES
BASIS FOR IMAGING AGENT DEVELOPMENT
he past two decades have witnessed major advances in the
nderlying molecular and cellular mechanisms of athero-
enesis and lesion progression (9–13). Fundamentally, the
rocess of inflammation regulates atherosclerosis (10,13)
Fig. 1). In particular, the macrophage has emerged as the
ey cellular mediator of inflammation in atheroma, and
articipates in all phases of atherogenesis, including lesion
nitiation, progression, and complication. Initially recruited
o the artery wall as monocytes, these cells mature into
acrophages. Once resident, macrophages ingest oxidized
ipoproteins via scavenger receptors, becoming foam cells,
nd contribute to atheroma expansion. A subset of macro-
hages can die within the atheroma, via oncosis and/or
poptosis (programmed cell death), leading to the develop-
ent of a paucicellular lipid core. In addition to imbibing
Table 1. Current High Priority Imaging Targe
Biological Process Class
Macrophage activity Surface receptors
Metabolism
Proteases
Peroxidases
Modified lipoproteins
Angiogenesis Increased vascularity and leak
Endothelium
Apoptosis Cell membrane
Enzymes
Cell trafficking Monocytes
Lymphocytes
Stem cells
Boldfaced agents have been clinically tested in human subjec
the next 3 to 5 years.
FDG  fluorodeoxyglucose; GLUT-1  glucose transpo
idase; MRI  magnetic resonance imaging; NIRF  near
Abbreviations and Acronyms
FDG  fluorodeoxyglucose
LDL  low-density lipoprotein
MMP  matrix metalloproteinase
MNP  magnetic nanoparticles (dextran-coated)
MPO  myeloperoxidase
MRI  magnetic resonance imaging
NIRF  near-infrared fluorescence or fluorochrome
PET  positron emission tomography
SPECT  single-photon emission computed tomography
VCAM  vascular cell adhesion moleculelipoprotein; PET  positron emission tomography; SPECT 
scavenger receptor A; VCAM  vascular cell adhesion molecule.ipid, macrophages produce and/or secrete a number of
roteases, such as cathepsins and matrix metalloproteinases
MMP) that can degrade the extracellular matrix compris-
ng the fibrous cap. Macrophages also secrete various
eactive oxygen species (e.g., products of NAD[P]H oxi-
ases or myeloperoxidase [MPO]) that can further modify
ipoproteins, setting up a vicious cycle of additional monocyte/
acrophage recruitment. Finally, autopsy studies have dem-
nstrated prominent macrophage accumulation in ruptured
therosclerotic lesions (30). These findings underscore a key
ole for macrophages in plaque complications (15).
The endothelium also contributes importantly to athero-
enesis. Via their recruitment of monocytes, endothelial
ells regulate early lesion development. Under inflammatory
onditions, endothelial cells express adhesion molecules
uch as vascular cell adhesion molecule (VCAM)-1;
CAM-1 can mediate the recruitment both monocytes and
lymphocytes into the nascent atheroma to foster lesion
volution (10). In addition, the fragile endothelium in
ngiogenic vessels, typically associated with v3 integrin
31), can promote lesion progression via intraplaque hem-
rrhage (32) and may produce plaque complications (15).
Thus, biological insights provide the foundation for the
evelopment of atherosclerosis-targeted imaging agents
Fig. 1, Table 1). The past two decades have witnessed
remendous growth in atherosclerosis imaging, and recent
eview articles summarize some of the experimental data
6–8,22–27). Many promising imaging agents, already
ndergoing experimental validation, may emerge in the
linical arena.
EW ATHEROSCLEROSIS IMAGING AGENTS:
INDOWS INTO IN VIVO BIOLOGY
molecular imaging agent (or imaging reporter) typically
onsists of two components: 1) a detection moiety, such as
radioisotope, magnetic compound, fluorochrome, or sonic
Atherosclerosis
Specific Molecular Targets
SRA, CD36, dextran receptor (magnetic
nanoparticles-MRI), others
Hexokinase, GLUT-1 (FDG-PET)
MMP (1, 8, 9, 13), cathepsins-NIRF* (B, S, K)
MPO
OxLDL, others
Perfusion markers
VCAM-1, v3* (angiogenesis-MRI), E-selectin
Phosphatidylserine (Annexin A5–SPECT)
Caspases, scramblases
gents that are expected to undergo clinical evaluation within
; MMP  matrix metalloproteinase; MPO  myeloperox-
ed fluorescence imaging; OxLDL  oxidized low-densityts in
age
ts. *A
rter-1
infrarsingle-photon emission computed tomography; SRA 
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Molecular Imaging of Atherosclerosis April 4, 2006:1328–38nhancer; and 2) a molecule-specific or cell-specific affinity
igand, such as an antibody, peptide, or small molecule (e.g.,
erived from diversity oriented synthesis). Clinically useful
olecular imaging agents report on specific biological pro-
esses, generate a strong signal (ideally when recognized by
ts target), possess favorable pharmacokinetics and biodis-
ribution, and exhibit an excellent safety profile. For these
easons not all biomarkers associated with atherosclerosis
29) furnish promising imaging targets. For example, se-
reted proteins or stationary receptors with low abundance
re difficult to target. Conversely, internalizing receptors,
bundant extracellular markers, and low-background
nzyme-sensing quenched substrates can provide high-yield
maging strategies (Table 1).
Reporter imaging agent technology has dovetailed ad-
ances in chemical biology, and now incorporates screening
pproaches using phage-display (33–35), nanoparticle li-
raries (36), and combinatorial chemistry (37). Equally
mportant, amplification strategies can enhance target signal
eneration and/or minimize background signal (6,38). Such
smart” agents (e.g., protease-activatable [39–42], or incor-
orating oligomerization of signal-producing substrates
43], cellular trapping of phosphorylated substrates [44],
nd covalent binding [45]) can provide high contrast-to-
oise ratios and thus prove particularly well suited for in vivo
maging.
MERGING CLINICAL APPLICATIONS
ith the recent advances in biology and imaging technol-
gy, molecular imaging studies now offer the ability to
isualize key biological signatures of atherosclerosis in vivo.
e anticipate that molecular imaging studies of atheroscle-
igure 1. The biology of atherosclerosis initiation, progression, and complic
maging agents are available for a range of targets and imaging modalities,
rom reference 10. CCR2 chemokine (CC motif) receptor 2; MCPmo
MP  matrix metalloproteinase; ROS  reactive oxygen species; VCAosis will prove useful in the following four clinical scenar- los: 1) identifying patients at high-risk for cardiovascular
vents (death, myocardial infarction, stroke) not identified
y routine clinical evaluation (e.g., history, physical exam,
lectrocardiogram, lipid profile, C-reactive protein, exercise
readmill testing); 2) characterizing the vulnerability of
esions in high-risk areas of the coronary vasculature (e.g.,
he proximal third of each of the coronary arteries [46])—
esions deemed particularly high-risk could eventually justify
ovel local therapies such as intracoronary drug-eluting
tents; 3) evaluating novel atherosclerotic therapies that
arget biology rather than the lipid profile (e.g., peroxisome
roliferator-activated receptors [47]); and 4) selecting indi-
idualized treatment strategies based on the molecular
rofile of vulnerable plaques identified in particular patients.
everal promising atherosclerosis-targeted imaging agents
ave already undergone testing in the clinic or are on the
linical horizon (Table 1).
ellular imaging of macrophage activity. RECEPTOR-
EDIATED UPTAKE. Most clinically tested magnetic nano-
articles (MNP) have carbohydrate coatings (dextrans or
tarch derivatives) that bind to and undergo endocytosis by
acrophages, presumably through dextran receptors (48) or
cavenger receptors. Long circulating MNP that targeted
issue macrophages were first developed in the late 1980s
49) and subsequently proved biocompatible and able to
ffect strong MRI contrast (R2  R1) in cells and in vivo
50,51). In atherosclerosis, preclinical studies with magne-
ofluorescent dextranated nanoparticles have demonstrated
referential uptake of dextranated MNP by lesional macro-
hages, with concomitant but much lower uptake by endo-
helial cells and smooth muscle cells (52). Recently, Kooi
t al. (53) and Trivedi et al. (54) have demonstrated that
s. This road map identifies important targets for molecular imaging (Table 1).
several agents have been tested in clinical studies. Modified by permission
e chemoattractant protein; M-CSFmonocyte colony-stimulating factor;
vascular cell adhesion molecule.ation
andong-circulating MNP (e.g., ferumoxtran, Advanced Mag-
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acrophage-rich human carotid endarterectomy specimens.
ymptomatic patients (n  19) scheduled for carotid
ndarterectomy underwent pre-contrast carotid MRI and
hen received an intravenous injection of ferumoxtran (2.6
g Fe/kg iron). After 24 h (and in one study serially up to
2 h), patients underwent repeat carotid MRI. Black-blood
2*-weighted imaging showed focal negative signal en-
ancement (darkening) within carotid atherosclerotic le-
ions (Fig. 2) (53,54). Histopathological correlation dem-
nstrated colocalization between macrophages and iron
eposition as detected by immunohistochemistry (Fig. 2) as
ell as electron microscopy. Slight uptake was noted in
igure 2. Cellular magnetic resonance image of macrophage (Mac) endoc
anoparticles. (A) Dextranated magnetic nanoparticle injection (ferumo
eurologically symptomatic patient (top, “Pre” and [57] “Post” images
emonstrates colocalization of macrophages (C, anti-CD68 macrophage an
ed counterstain; original magnification 400). Images provided court
r. Martin Graves, Addenbrooke’s Hospital, Cambridge, United Kingdo
esonance image and near infrared fluorescent imaging of murine atheroscl
lectrocardiogram- and respiratory-gated magnetic resonance image of an a
uorescent dextranated magnetic nanoparticle (15 mg/kg of iron, 24 h circ
f atherosclerosis in the apo E/mouse. (F) Fluorescence reflectance ima
he aortic root (arrow). (G) On fluorescence microscopy, the near-infrare
ortic root plaque sections (original magnification 200). In contrast, sm
ntibody, green) modestly colocalize with the MFNP.ther cells such as smooth muscle cells and endothelial cells, Nnd specimens from control patients without MNP showed
inimal iron deposition (53). A recent experimental study
xtended these results by quantifying the cellular distribution
f MNP in atherosclerosis using a multimodality MRI and
ear-infrared fluorescence (NIRF) magnetofluorescent nano-
article (52).
Together these results demonstrate that MNP-enhanced
RI can identify macrophage-rich atheromata. To become
seful for coronary plaque imaging, post-MNP magnetic
esonance images will require higher resolution and signal-
o-noise ratios, possibly via intravascular magnetic reso-
ance coils (55,56) or novel pulse sequences (57). Alterna-
ively, newer MNP, such as those that permit concomitant
in clinical (53,54) and experimental (52) atherosclerosis using magnetic
, 2.6 mg/kg) produces focal signal loss within a carotid plaque of a
w). Histological examination of the carotid endarterectomy specimen
y, original magnification 100), and iron (Fe) (D, Perls iron stain, neutral
f Dr. Jonathan Gillard, Dr. Rikin Trivedi, Dr. Simon Howarth, and
eproduced by permission from reference 8. (B) Multimodality magnetic
using a magnetofluorescent nanoparticle (MFNP) (52). (E) In vivo 9.4-T
oprotein E/-deficient mouse. Injection of a clinical-type near infrared
n time) produces focal signal loss (arrow) in the aortic root, a known site
f the resected aorta confirms a focal near-infrared fluorescent signal within
rescent MFNP accumulates in intimal macrophages (red, arrow) within
muscle cells (stained here with a spectrally distinct -actin fluorescentytosis
xtran
, arro
tibod
esy o
m. R
erosis
polip
ulatio
ging o
d fluoIRF imaging (52), may allow sequential optical imaging of
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Molecular Imaging of Atherosclerosis April 4, 2006:1328–38oronary plaque macrophages, possibly via intravascular
IRF catheters (58). Finally, newer derivatized MNP (i.e.,
hose with affinity ligands conjugated to the dextran coat
35,59]) offer the potential to improve substantially the
ensitivity and specificity of MNP uptake by activated
acrophages (59).
ETABOLISM. 18Fluorodeoxyglucose (18FDG), a positron
mission tomography (PET) radiotracer, competes with
lucose for uptake into metabolically active cells including
acrophages in atheromata (44). Fluorodeoxyglucose is
rapped inside cells after phosphorylation. Rudd et al. (44)
mployed 18FDG to image plaque inflammation in patients
ith symptomatic carotid atherosclerosis (Fig. 3). Patients
n  8) who had experienced a recent carotid arterial
schemic event and had an internal carotid artery lesion
70% stenosis received an intravenous injection of 18FDG,
nd then underwent PET imaging 3 h later. Rigorous
o-registration with subsequently acquired cranial computed
omography images demonstrated focal 18FDG uptake in
arotid plaques (Fig. 3). Examination of the surgically
esected plaque specimens demonstrated heavy macrophage
nfiltration. Corroborating microautoradiography experi-
ents revealed focal uptake of tritiated deoxyglucose, an
nalog of 18FDG, into macrophage-rich plaque sections,
ith minimal uptake in other areas of plaques or in control
igure 3. Cellular imaging of macrophage metabolism using 18F-fluorod
omputed tomography (middle), and offline co-registered positron emi
ymptomatic patient who received an intravenous bolus of 18FDG (dose 37
ptake by a right carotid plaque (arrow), corroborated by the computed tom
omography images. (B) Relatively weaker 18FDG accumulation is seen i
arotid plaque from a symptomatic patient was incubated with tritiated deo
100) shows colocalization of silver grains with plaque macrophages (D,
rovided courtesy of Dr. James Rudd and Dr. Peter Weissberg, Addenb
rom reference 44.ections. It still remains unsettled whether appreciable aackground 18FDG signal is present in other metabolically
ctive arterial cells (e.g., smooth muscle cells) in vulnerable
laque.
18Fluorodeoxyglucose uptake occurred variably in the
ontralateral asymptomatic plaques in six of eight patients,
nd did not occur in normal carotid arteries. These findings
emonstrate that 18FDG PET could be useful in identifying
nflamed subclinical carotid lesions. The advent of inte-
rated PET-computed tomography scanners should further
mprove image quality with the 18FDG method. However,
his approach will likely prove less suitable for detecting
oronary atheromata due to high 18FDG cardiac uptake by
etabolically active cardiomyocytes (25). Alternative PET
racers for imaging macrophages include the benzodiazepine
eceptor-targeted agent 11C(R)-PK11195 (60), as well as a
umber of experimental agents under development such as
agged affinity peptides.
olecular imaging of protease activity. CATHEPSINS. The
athepsin family includes cysteine proteases overexpressed
n human and experimental atherosclerosis (61). Produced
y macrophages, endothelial cells, and smooth muscle cells,
athepsins S and K can degrade extracellular matrix via their
lastase and/or collagenase properties and therefore may
articipate in plaque destabilization (62). Recently, Chen et al.
41) optically imaged cathepsin B activity in experimental
lucose (18FDG) (44). (A) Positron emission tomography (left), contrast
tomography/computed tomography (right) images of a neurologically
bq). The positron emission tomography image demonstrates focal 18FDG
hy angiogram and co-registered positron emission tomography/computed
carotid plaque of an asymptomatic patient. (C, D) A surgically resected
cose, an analogue of 18FDG. Autoradiography (C, original magnification
D68 antibody, 200) in areas of the fibrous cap and lipid core. Images
e’s Hospital, Cambridge, United Kingdom. Reproduced by permissioneoxyg
ssion
0 M
ograp
n the
xyglu
anti-Ctherosclerosis in vivo. The authors employed an NIRF-
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April 4, 2006:1328–38 Molecular Imaging of Atherosclerosisctivatable imaging agent that became brightly fluorescent
fter enzymatic cleavage by cathepsin B (39). Using nonin-
asive fluorescence-mediated tomography (63) co-registered
ith MRI, atherosclerotic lesions in mice became brightly
uorescent 24 h after receiving a systemic injection of the
gent (Fig. 4). Ex vivo fluorescence reflectance imaging
onfirmed focal NIRF signal in atheroma, and correlative
uorescence microscopy revealed cathepsin B and macro-
hage colocalization with NIRF signal in microscopic
ections.
This study demonstrated that protease activity could serve
s a useful imaging biomarker for detecting inflammation in
therosclerosis. A version of this agent is under develop-
ent for clinical trials (8), and may offer an approach to
etect inflamed plaques. Although depth penetration limits
ertain optical imaging methods, near-infrared photons can
e tomographically reconstructed, offering the potential for
eep tissue imaging in vivo (38). In addition, NIRF imaging
atheters (58) and handheld reflectance devices are under-
oing rapid translation into the clinic. In concert with
rotease activatable imaging agents, these devices could
dentify inflamed coronary and carotid plaques in vivo.
dditional protease-activatable NIRF agents, for example
or cathepsin K (62), may provide new inflammatory read-
uts for atherosclerosis (64).
MPs. Members of the MMP family of zinc-dependent
ndopeptidases can also degrade extracellular matrix mac-
omolecules including elastin and collagen. Heightened
ctivity of MMPs in human plaques and experiments in
enetically altered mice suggest a causative role for MMPs
n plaque destabilization, particularly in lesions with positive
expansive, outward, compensatory) remodeling (65–68).
igure 4. Molecular imaging of cathepsin B protease activity in atheroscle
gent (41). (A) In vivo murine magnetic resonance image of an aortic plaque
ediated tomography, a three-dimensional noninvasive and quantitative fl
orrelate well with (D) protease-generated NIRF signal within plaques. (E
ith (F) focal NIRF signal on microscopic sections, consistent with catheps
eference 41.ecently, Schäfers et al. (69) performed an in vivo single- Mhoton emission computed tomography (SPECT) biodis-
ribution imaging study of a broad-spectrum MMP inhib-
tor. The 123I- or 125I-radiolabeled imaging agent derived
rom a compound that binds to the active catalytic site
f MMPs (70). Using atherosclerotic apolipoprotein
-deficient (apo E /) mice, the authors demonstrated
ocal signal enhancement of carotid plaques in animals
eceiving an intravenous injection of the agent, validated by
25I autoradiography in situ. Animals pre-treated with the
nlabeled MMP inhibitor parent compound showed mini-
al signal. Further studies may help to determine the
recise relationship between the radiolabeled active site
igand and MMP activity.
Imaging of MMP activity in atherosclerosis therefore
ffers another method for detecting inflamed atherosclerotic
esions. With the typical resolution of clinical SPECT
ystems (10 mm), 123I scintigraphy of MMP-rich carotid
laques may prove feasible using Schäfers’ agent, particu-
arly in concert with integrated SPECT-computed tomog-
aphy systems. A gelatinase MMP-activatable NIRF agent
71) may furnish another option for imaging of MMP
ctivity at higher resolution in vivo (72).
maging of MPO activity. Myeloperoxidase, a member of
he heme peroxidase superfamily capable of generating the
xidant species hypochlorous acid, is biologically and clin-
cally linked to atherosclerosis (73,74). Myeloperoxidase
ocalizes within human atherosclerotic plaques (75,76), and
ts products may promote atherogenesis by modifying low-
ensity lipoproteins (LDL) to an atherogenic form, func-
ionally inactivating high-density lipoproteins, activating
MPs, causing endothelial cell apoptosis and tissue factor
elease, and inactivating nitric oxide (73,77). A number of
using an injectable protease-activatable near-infrared fluorescent (NIRF)
w) co-registers with NIRF signal enhancement on (B) in vivo fluorescence
ence imaging method (63). (C) Sudan IV-stained lipid-rich aortic lesions
unoreactive cathepsin B enzyme (200 original magnification) correlates
mediated activation of the imaging agent. Reproduced by permission fromrosis
(arro
uoresc
) ImmRI and nuclear imaging substrates for MPO are now
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Molecular Imaging of Atherosclerosis April 4, 2006:1328–38vailable (78–82). Myeloperoxidase-induced oligomeriza-
ion of these substrates produces high target-to-background
ignal levels via chemical amplification (e.g., enhanced
elaxivity of paramagnetic [78–80] or superparamagnetic
ompounds [81]) and/or biological amplification (e.g., en-
anced accumulation of larger substrates [82]) strategies.
ngoing investigation in atherosclerotic animals will deter-
ine the utility of these and novel MPO sensors.
maging of lipoproteins. LDL. Low-density lipoprotein
ontributes importantly to atherosclerosis initiation and
rogression (9,10), and the presence of a large lipid core is
high-risk feature of coronary plaques (15). When modified
o an oxidized form (e.g., by MPO products, as discussed in
he preceding text), oxidized LDL particles become proin-
ammatory and can promote recruitment and activation
f monocytes in evolving atheromata. Low-density li-
oprotein was recognized as a scintigraphic imaging
arget over 20 years ago, and reached clinical evaluation
sing 99mTc-labeled LDL (83). However, insufficient
arget-to-background ratios limited its applicability for
oronary-sized lesions (24). Newer imaging targets include
xidized LDL epitopes, recently shown to be associated
ith coronary artery disease (84). Tsimikas et al. (85) have
eveloped radiolabeled oxidation-specific antibodies to tar-
et oxidized LDL in experimental atheroma in vivo (86,87).
urther studies will determine the potential of these agents
or perhaps magnetic and/or fluorescent analogs) and new
ipoprotein-targeted agents (88,89) for the clinical detection
f lipoprotein-rich plaques.
igure 5. Molecular imaging of apoptosis in atherosclerosis using radiolabe
A, single-photon emission computed tomography images, arrows) of a
ections of the resected plaque stains strongly (B, anti-annexin A5 polyclona
inimal annexin A5 signal (C) appears in the carotid artery of a patient wn the corresponding smooth muscle cell-rich lesion. Images provided courtesy
aastricht, Maastricht, the Netherlands. Reproduced by permission from refermaging of apoptosis. Apoptosis or programmed cell
eath may contribute to atherosclerotic plaque vulnerability
10,15,90,91). During the process of apoptosis, phosphati-
ylserine, a phospholipid normally residing on the inner cell
embrane of viable cells, becomes exteriorized and thus
vailable to affinity ligands such as annexin V. Several
cintigraphic imaging agents have been developed based on
nnexin V (e.g., 99mTc- and 123I-labeled annexin V for
PECT imaging, and 124I- and 18F-labeled annexin V for
ET imaging). In an experimental atherosclerosis imaging
tudy, Kolodgie et al. (92) demonstrated strong uptake of
adiolabeled 99mTc annexin V in the balloon-injured aortas
f cholesterol-fed rabbits. A good correlation was seen
etween lesional radiotracer uptake and macrophage con-
ent. In vivo however, annexin V can also bind necrotic cells
nd platelets, and can enter macrophages, thereby dimin-
shing the specificity for apoptotic cells that the agent
xhibits in vitro (93).
In a clinical extension of this work, Kietselaer et al. (94)
ecently demonstrated in vivo uptake of radiolabeled an-
exin A5 (renamed from annexin V) into carotid plaques
ontaining markers of instability, including macrophages,
nfiltrates, and intraplaque hemorrhage (Fig. 5). Two carotid
laques with stable histological features did not appreciably
ake up the imaging agent. Radiolabeled annexin A5 thus
rovides another clinical option for imaging carotid ather-
ma. For imaging of apoptotic coronary plaques, higher
esolution imaging agents such as an annexin V magneto-
nexin (94). 99mTc-radiolabeled annexin A5 accumulates in a carotid lesion
t with a recent transient ischemic attack (TIA). (B, D) Annexin A5 in
body, original magnification400) in a macrophage-rich area. In contrast,
remote TIA. (D) Annexin A5 immunoreactivity is at a background levelled an
patien
l anti
ith aof Dr. Bas Kietselaer and Dr. Leonard Hofstra, University Hospital of
ence 94. ant  anterior; l  left.
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poptosis imaging capabilities.
maging of angiogenesis. VCAM-1. Due to their potential
o promote intraplaque hemorrhage and subsequent choles-
erol deposition and plaque growth (96), plaque neovessels
ay mark plaque vulnerability (15,90). Microvessels in
uman atheromata can overexpress the leukocyte adhesion
olecule VCAM-1, a ligand for the 41 integrin very late
ntigen-4, and indicate ongoing inflammation within
laques (97). Recently, two new VCAM-1–targeted imag-
ng agents have been investigated in atherosclerosis (35,98).
elly et al. (35) identified a novel VCAM-1 peptide affinity
igand from phage display that is actively internalized by
ells expressing VCAM-1. Conjugation of the ligand to a
agnetofluorescent nanoparticle enabled direct MRI and
IRF imaging of VCAM-1 expression in murine athero-
clerosis, validated by correlative NIRF microscopy and
mmunohistochemistry. Hamilton et al. (98) synthesized
CAM-1–targeted echogenic immunoliposomes using a
ommercially available VCAM-1 antibody as an affinity
igand. Intravascular ultrasound imaging of the VCAM-1–
argeted agent in balloon-injured carotid arteries of
holesterol-fed swine demonstrated intimal signal enhance-
ent after agent injection. Further studies may determine
ts specificity for atheroma compared to nondiseased arterial
egments (99).
NTEGRIN v3. Neovascular endothelial cells also charac-
eristically express integrin v3, a heterodimeric protein
hat localizes to human atherosclerotic plaques, particularly
ithin the vasa vasorum and intraplaque microvessels (100).
o image v3 expression in early atherosclerosis, Winter
t al. (101) conjugated an arginine-glycine-aspartic acid
RGD) peptidometic to a gadolinium-coated (90,000
olecules) perfluorocarbon. Using cholesterol-fed rabbits
ith intimal hyperplasia, the v3-targeted agent showed
urable plaque signal enhancement on in vivo MRI. His-
ological examination revealed colocalization of v3 with
ndothelial cells lining the vasa vasorum. Magnetic reso-
ance imaging of v3 expression may therefore permit
etection of atherosclerotic lesions with abundant neoves-
els. Further investigation to determine whether the aug-
ented v3 signal in atherosclerotic plaques suffices to
istinguish plaques from normal coronary arteries that
xpress v3 at baseline (100). Other v3-targeted imaging
gents have been designed for ultrasound (102), PET (103),
PECT (104,105), NIRF (106), and MRI (107), and could
lso be applied to atherosclerosis. Finally, another promising
trategy for imaging angiogenesis targets the extra-domain
of fibronectin, an extracellular matrix protein found in
dvanced atherosclerotic lesions (108).
UTLOOK
olecular imaging studies can now elucidate biological
spects of atherosclerosis in vivo, and the field is moving
apidly toward the clinical detection of high-risk atheromaTable 1). Targeted and activatable imaging agents now
nder development use a variety of imaging platforms
ncluding MRI, nuclear, NIRF, and ultrasound. To achieve
linical utility for the evaluation of atherosclerotic plaques,
olecular imaging studies must: 1) provide outcome infor-
ation beyond that of clinical (e.g., Framingham risk score)
nd emerging biomarker (e.g., C-reactive protein) risk
ssessments; 2) be compared to imaging methods that
ddress plaque anatomy (e.g., noncontrast-enhanced MRI,
ntravascular ultrasound, optical coherence tomography,
ear infrared spectroscopy); and 3) accurately report on the
iological process targeted by the agent. These requirements
ill undoubtedly require prospective clinical trials that
valuate novel imaging agents with histological end points
e.g., carotid endarterectomy specimens retrieved after agent
njection), imaging end points (e.g., statin-mediated reduc-
ions in macrophage or protease activity), and, ultimately,
linical end points (e.g., new-onset angina, myocardial
nfarction, stroke, or death).
Patients likely recruited for such trials include those with
ndications for invasive procedures such as carotid endarter-
ctomy (atheroma specimen retrieval) and cardiac catheter-
zation (nonculprit lesion assessment after culprit lesion
ercutaneous coronary intervention) as well as patients with
ery high Framingham risk scores (e.g., 10-year risk of
onfatal myocardial infarction or death 20%), particularly
f noninvasive molecular imaging options are available.
nitial molecular imaging trials likely will focus on imaging
gent validation in atheroma specimens, primarily by cor-
elating plaque imaging signals with the histological pres-
nce of the expected biological target. Secondary trials will
hen determine the ability of a given molecular imaging
gent to predict cardiovascular risk in outcome-driven,
atural history studies of vulnerable plaques.
Although likely to require substantial effort and cost,
ompletion of such trials will be of pivotal importance to
atients and apparently healthy individuals at high risk for
he consequences of atheroma progression and rupture. If
redictive beyond conventional risk assessment, we envision
hat molecular imaging of atherosclerosis, in concert with
natomical imaging techniques, will prove instrumental in
uiding the detection, risk stratification, systemic therapy
e.g., optimal medications and doses), and local treatment
e.g., intracoronary stenting) of this disease.
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